Optimizing Decision-Making in CLL in an Era of Novel Agents

A comprehensive educational program featuring expert insight commentaries, an Interactive Treatment Decision Support tool, and a series of microeducation modules to fortify your practice in managing patients with CLL.
Jeff P. Sharman, MD
Program Director
Jeremy S. Abramson, MD, MMSc
Matthew S. Davids, MD, MMSc
Anthony Mato, MD
Jeff P. Sharman, MD

Microlearning Interactive Virtual Presentations

In this installment of CCO’s concise patient case series, Matthew S. Davids, MD, MMSc, discusses first-line treatment considerations for a patient with CLL with a del(17p) alteration.

Jeff P. Sharman, MD
Program Director
Matthew S. Davids, MD, MMSc
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 28, 2020 Expired: September 27, 2021

In this installment of CCO’s concise patient case series, Jeff P. Sharman, MD, discusses first-line treatment considerations for a fit patient with CLL and no high-risk features.

Jeff P. Sharman, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 28, 2020 Expired: September 27, 2021

In this installment of CCO’s concise patient case series, Jeremy S. Abramson, MD, MMSc, discusses first-line treatment considerations for an older patient with CLL.

Jeff P. Sharman, MD
Program Director
Jeremy S. Abramson, MD, MMSc
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 12, 2020 Expired: October 11, 2021

In this installment of CCO’s concise patient case series, Matthew S. Davids, MD, MMSc, discusses second-line treatment considerations for a patient with CLL who received previous chemoimmunotherapy.

Jeff P. Sharman, MD
Program Director
Matthew S. Davids, MD, MMSc
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 28, 2020 Expired: September 27, 2021

In this installment of CCO’s concise patient case series, Jeff P. Sharman, MD, discusses treatment considerations for a patient with CLL who initially progressed on chemoimmunotherapy and was intolerant to subsequent ibrutinib.

Jeff P. Sharman, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 1, 2020 Expired: September 30, 2021

In this installment of CCO’s concise patient case series, Jeremy S. Abramson, MD, MMSc, discusses treatment considerations for a patient with CLL requiring new treatment following BTK inhibitor– and venetoclax-based therapy.

Jeff P. Sharman, MD
Program Director
Jeremy S. Abramson, MD, MMSc
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 14, 2020 Expired: October 13, 2021

Downloadable Slidesets

Download this slideset for expert perspectives on first-line treatment considerations for a patient with CLL with a del(17p) alteration.

Matthew S. Davids, MD, MMSc Released: September 28, 2020

Download this slideset for expert perspectives on first-line treatment considerations for a fit patient with CLL and no high-risk features.

Jeff P. Sharman, MD Released: September 28, 2020

Download this slideset for expert perspectives on first-line treatment considerations for an older patient with CLL.

Jeremy S. Abramson, MD, MMSc Released: October 12, 2020

Download this slideset for expert perspectives on second-line treatment considerations for a patient with CLL who received previous chemoimmunotherapy.

Matthew S. Davids, MD, MMSc Released: September 28, 2020

Download this slideset for expert perspectives on treatment considerations for a patient with CLL who initially progressed on chemoimmunotherapy and was intolerant to subsequent ibrutinib.

Jeff P. Sharman, MD Released: October 1, 2020

Download this slideset for expert perspectives on third-line treatment considerations for patients with CLL requiring new treatment following BTK inhibitor– and venetoclax-based therapy.

Jeremy S. Abramson, MD, MMSc Released: October 14, 2020

ClinicalThought

With the recent approval of ibrutinib plus rituximab for the frontline treatment of CLL, how should therapeutic choices be made in an increasingly complex landscape? Here’s my approach.

Anthony Mato, MD Released: June 26, 2020

Interactive Decision Support Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with CLL with those of 5 renowned experts.

Jeff P. Sharman, MD
Program Director
Released: November 20, 2020
Provided by University of South Florida (USF) Health in partnership with Clinical Care Options, LLC

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

Produced in collaboration with
CLL Society Logo
Educational grant provided by:
AbbVie Inc.
AstraZeneca
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue